One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging
European Journal of Nuclear Medicine and Molecular Imaging · 2025-06 · 52 (7) · 2463-2476
DOI: 10.1007/s00259-025-07073-w ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 30.01.2025. Verfasst von Eduardo Calderón und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Otfried-Mueller-Str. 14, 72076, Tuebingen, Germany. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Tübingen.
Abstract (Originalsprache)
Purpose
Somatostatin receptor (SSTR)-PET is crucial for effective treatment stratification of neuroendocrine neoplasms (NENs). In highly proliferating or poorly differentiated NENs, dual-tracer approaches using additional [ 18 F]FDG PET can effectively identify SSTR-negative disease, usually requiring separate imaging sessions. We evaluated the feasibility of a one-day dual-tracer imaging protocol with a low activity [ 18 F]FDG PET followed by an SSTR-PET using the recently introduced [ 18 F]SiFA lin -TATE tracer in a long axial field-of-view (LAFOV) PET/CT scanner and its implications in patient management.
Methods
Twenty NEN patients were included in this study. Initially, a low activity [ 18 F]FDG PET was performed (0.5 ± 0.01 MBq/kg; PET scan 60 min p.i.). After 4.2 ± 0.09 h after completion of the [ 18 F]FDG PET, a standard activity of [ 18 F]SiFA lin -TATE was administered (3.0 MBq/kg; PET scan 90 min p.i.). To ensure the quantification accuracy of the second scan, we evaluated the potential impact of residual [ 18 F]FDG activity by segmenting organs with minimal physiological SSTR-tracer uptake, such as the brain and myocardium, and assessing the activity concentrations (ACTs) of tumor lesions. Residual tumor lesion ACTs of [ 18 F]FDG were calculated by factoring fluorine-18 decay, identifying a maximum residual ACT of 15% (R15%). To account for increased [ 18 F]FDG trapping over time, higher residual ACTs of 20% (R20%) were considered. These simulated [ 18 F]FDG ACTs were compared with those measured in the second PET scan with [ 18 F]SiFA lin -TATE. The influence of the dual-tracer PET/CT results on therapeutic strategies was evaluated. Results [ 18 F]FDG cerebral uptake significantly decreased in the subsequent SSTR-PET (mean uptake [ 18 F]FDG: SUV mean 6.0 ± 0.4; mean uptake in [ 18 F]SiFA lin -TATE PET: SUV mean 0.2 ± 0.01; p < 0.0001); with similar results recorded for the myocardium. Simulated residual [ 18 F]FDG ACTs represented only a minimal percentage of ACTs measured in the tumor lesions from the second PET scan (R15%: mean 5.2 ± 0.9% and R20%: mean 6.8 ± 1.2%), indicating only minimal residual activity of [ 18 F]FDG that might interfere with the second PET scan using [ 18 F]SiFA lin -TATE and preserved semi-quantification of the latter. Dual-tracer PET/CT findings directly influenced changes in therapy plans in eleven (55%) of the examined patients.
Conclusion
LAFOV PET scanners enable a one-day dual-tracer protocol, providing diagnostic image quality while preserving the semi-quantification of two 18 F-labeled radiotracers, potentially simplifying the assessment of tumor biology and improving the clinical patient management while reducing logistical challenges. Additionally, low-activity PET imaging facilitates one-day dual-tracer PET examinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Otfried-Mueller-Str. 14, 72076, Tuebingen, Germany.
- Werner Siemens Imaging Center, Preclinical Imaging and Radiopharmacy, Eberhard-Karls University, Roentgenweg 13, 72076, Tuebingen, Germany.
- Diagnostic and Interventional Radiology, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany.
- Department of Pathology, University Hospital Tuebingen, Liebermeisterstr. 8, 72076, Tuebingen, Germany.
- DFG Cluster of Excellence 2180 'Image-Guided and Functional Instructed Tumor Therapy' (iFIT), University of Tuebingen, Roentgenweg 11, 72076, Tuebingen, Germany.
- Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tuebingen, Otfried- Mueller-Str. 14, 72076, Tuebingen, Germany.
ORCID-Profile: Eduardo Calderón, Christian la Fougère, Nils F Trautwein
Förderung
- Universitätsklinikum Tübingen
Zitieren
APA
Calderón, E., Kiefer, L. S., Schmidt, F. P., Lan, W., Brendlin, A. S., Reinert, C. P., Singer, S., Reischl, G., Hinterleitner, M., Dittmann, H., la Fougère, C., & Trautwein, N. F. (2025). One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 52(7), 2463-2476. https://doi.org/10.1007/s00259-025-07073-w
Vancouver
Calderón E, Kiefer LS, Schmidt FP, Lan W, Brendlin AS, Reinert CP, et al. One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(7):2463-2476. doi:10.1007/s00259-025-07073-w
BibTeX
@article{Caldern2025,
author = {Calderón, Eduardo and Kiefer, Lena S and Schmidt, Fabian P and Lan, Wenhong and Brendlin, Andreas S and Reinert, Christian P and Singer, Stephan and Reischl, Gerald and Hinterleitner, Martina and Dittmann, Helmut and la Fougère, Christian and Trautwein, Nils F},
title = {One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {52},
number = {7},
pages = {2463--2476},
doi = {10.1007/s00259-025-07073-w}
}
EUVIMED